Regeneron Pharma Tops Its Buy Zone Despite Mixed Sales For Blockbuster Eye Drug
Investor's Business DailyRegeneron stock edged higher Thursday despite mixed results for its bread-and-butter eye-disease treatment franchise, Eylea.
The post Regeneron Pharma Tops Its Buy Zone Despite Mixed Sales For Blockbuster Eye Drug appeared first on Investor's Busi…